Clinical trials in Greece

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

This study is testing new combinations of medicines (Retifanlimab, INCAGN02385, and INCAGN02390) for people with advanced head and neck cancer that has a specific marker called PD-L1. It aims to see if these combinations can stop the cancer from growing for longer.

An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

This study looks at a new medicine called efgartigimod for adults with Bullous Pemphigoid. It's an ongoing study to see how safe and effective the medicine is long-term, and how well it helps manage symptoms and improve quality of life.

Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction (HF-REVERT)

This study looks at a new treatment (CDR132L) for people who have had a heart attack and now have weakened heart pumping. It aims to see if the treatment helps the heart recover and is safe to use. Patients will either get the new treatment or a dummy treatment.

Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

This study compares a new medicine called Sacituzumab Govitecan with standard treatments for advanced bladder cancer that has spread or can't be removed. Researchers want to see if the new medicine helps people live longer and feel better.

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

This study is looking into a new medicine, finerenone, for children aged 6 months to 17 years with heart failure. It aims to see if finerenone, when added to their usual treatment, can help their heart pump better and if it is safe to use.

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

This study looks at a new way to treat advanced head and neck cancer in older patients not suitable for standard chemotherapy. It combines a special gel (NBTXR3) with usual radiotherapy, sometimes with another drug (Cetuximab, also known as Erbitux), to see if it helps patients live longer without their cancer getting worse.

Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia

This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

This study is looking into a new treatment called birtamimab for people with a serious heart condition called AL amyloidosis. Researchers want to see if birtamimab, given with standard care, can help people live longer compared to standard care alone.

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis

This study is testing a new medicine, empasiprubart, for adults with a condition called dermatomyositis. It's looking at how safe the medicine is, if people can tolerate it, and if it helps improve their symptoms. Some people will get the new medicine, and others will get a dummy treatment (placebo).

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

This study is looking into a new medication, JNJ-67953964, to help stop depression from coming back in people who also feel unable to experience pleasure. It compares this new drug with a dummy pill, alongside standard antidepressant treatment, to see how well it works.

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]

This study is looking at a new treatment for advanced skin cancer (cutaneous squamous cell carcinoma). It's testing a drug called cemiplimab, either alone or with another treatment called Vusolimogene oderparepvec, to see how well they shrink tumours and if they are safe.

A relative bioavailability study between a fixed dose combination product of Ibuprofen and Paracetamol vs. free combination of Ibuprofen and Paracetamol

This study is looking at a new combination medicine of ibuprofen and paracetamol for cold, flu, pain, and fever. We want to see how well the combined tablet works compared to taking the two medicines separately, checking if your body uses them in the same way.

Randomized, double-blind, phase 2 clinical trial controlled with conventional Bacillus Calmette-Guérin (BCG) vaccine to evaluate the safety and immunogenicity of a recombinant BCG vaccine that expresses the respiratory syncytial virus (RSV) nucleoprotein (N) (rBCG-N-RSV) in adults over 60 years of age.

This study is testing a new version of the BCG vaccine, designed to protect against both tuberculosis and RSV (a common winter cold virus), in people over 60. We want to see how safe it is and how well it helps the body fight off these infections.

Randomized, double-blind, parallel-groups, active - and placebo-controlled study to Evaluate the efficacy of a fixed combination of diclofenac 75 mg + thiocolchicoside 4 mg as solution for injection, in reLIEving back pain symptoms. Controlled study vs. dicloFenac 75 mg solution for injection and placebo. RELIEF Study

This study, called RELIEF, is looking at a new injection combining two medicines, diclofenac and thiocolchicoside, to see how well it treats lower back pain. It compares this combination to diclofenac alone and to a placebo (a dummy injection) to find the most effective treatment.

A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors

This study is testing a new medicine called RP3, sometimes with another medicine called Nivolumab, for people with advanced cancers. It's the very first time these treatments are being given to humans, to see how safe they are and what effects they have.

A Randomized Trial of the I-BFM-SG for the Management of Childhood non-mature-B Acute Lymphoblastic Leukemia

This study is looking at new treatments for a type of childhood leukaemia. It aims to see if adding Riximyo to standard chemotherapy helps children live longer without the leukaemia coming back. The study also checks for side effects.

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (OPERA-T study)

This study is looking into a new treatment for a serious lung infection called refractory invasive pulmonary aspergillosis. It's testing if adding a special mist (nebulized PC945) to usual medicines helps people get better. We want to see how many people improve after 12 weeks.

A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment

This study looks at a new combination of medicines, including isatuximab, for people newly diagnosed with multiple myeloma and kidney problems. Researchers want to see how well these treatments help reduce kidney damage and slow down the myeloma.

A Study of Daratumumab

This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.

EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation

This study looks at a medicine called Lixiana for people with a heart problem called atrial fibrillation who have also had a brain bleed. It checks if the medicine can stop strokes while being safe when it comes to serious bleeding.

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

This study is looking at a new medicine called SHP611 for children with Metachromatic Leukodystrophy (MLD). Doctors want to see if SHP611, given into the spinal fluid, can help children keep their ability to move around for longer. It also looks at how it affects speech and if it's safe.

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

This study is testing a new tablet medicine called etavopivat for people aged 12 to 65 with sickle cell disease. It aims to see if the medicine can improve a patient's red blood cells and reduce painful sickle cell crises. Half the group will receive the new treatment, the other a placebo.

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

This study looks at real-world results for men with prostate cancer that has spread and is sensitive to hormones. It compares two medicines, apalutamide and enzalutamide, which are given alongside standard hormone therapy to see how well they work.

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

This study is testing a new medicine, Deucravacitinib, for adults with an active form of Sjögren's Syndrome. Researchers want to see if it's safe and effective compared to a dummy pill. It's a key step to finding better treatments for this autoimmune condition.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

This study looks at a new drug, TAK-279, for people aged 18-75 with Crohn's disease that isn't well-controlled. We want to see if it reduces gut inflammation and is safe, compared to a dummy drug. It lasts about one year.

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

This study is looking into a new medication called brepocitinib for adults with a type of eye inflammation called non-infectious uveitis. It aims to see how well it works and if it's safe to use for managing this condition.

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

This study is looking at a new medicine called fenebrutinib for people with a type of multiple sclerosis (MS) called relapsing MS. It compares fenebrutinib to an existing medicine, teriflunomide, to see if it works better and is safe.

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

This study is testing a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy. We want to see if it's safe and helps slow down kidney damage, especially for those at higher risk.

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

This study looks at how a special feature called TriageHF on Medtronic heart devices helps people with heart failure. Researchers will watch how these devices are used in everyday care to see how well they work after being released for general use.

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

This study is looking at a new medicine called crizanlizumab to see if two different doses can help teenagers and adults with sickle cell disease. We want to find out if it's safe and if it can reduce pain crises (VOCs) compared to a dummy medicine (placebo).

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

This study looks at how a medicine called upadacitinib works for adults with moderate to severe Ulcerative Colitis in everyday life. Researchers will check its safety and how well it helps manage the condition, following about 1000 people over three years.

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

This study looks at how often people with certain types of epidermolysis bullosa (EB) get skin cancer, especially if they are using a gel called Filsuvez. It follows patients over five years to see if Filsuvez affects their risk of developing skin cancers.

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

This study looks at the long-term safety and effectiveness of a drug called Danicopan. It's for people with a rare blood condition called PNH who are already taking another PNH medicine, a C5 inhibitor. Danicopan is given as an add-on treatment.

Valved Graft PMCF Study

This study looks at how well a new type of heart valve called an 'Abbott Valved Graft' works in people with certain heart conditions. Doctors want to see if it's safe and effective after it's been used in patients in many hospitals around the world.